Zero incidence of major adverse cardiovascular events including no major strokes
BOSTON, MA / ACCESSWIRE / May 17, 2017 / InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a
leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the
publication of the Investigator Initiated IRON-GUARD Italian clinical registry in the peer reviewed journal EuroIntervention, which
appeared in the May 9th issue. IRON-GUARD was an independent, multicentre, multi-disciplinary clinical study treating patients with
carotid artery disease using the CGuardTM EPS (embolic prevention system) in 12 Italian centers.
The IRON-GUARD registry enrolled 200 patients, and showed results of 100% technical success placing the device, and zero
incidence of major adverse cardiovascular events (MACE), comprised of death, major stroke or myocardial infarction, in all patients
at 30 days. Five (2.5%) minor strokes and two transient ischemic attacks (1%) were observed, which were resolved by 30 days.
Study authors included Professor Carlo Setacci, MD, Francesco Spezialie, MD; Laura Capoccia, MD; Pasqualino Sirignano, MD;
Wassim Mansour, MD: Chiara Pranteda, MD; and Renato Casana, MD.
Dr. Francesco Spezialie, stated, "In our multi-center, multi-specialty experience, use of the CGuard EPS in routine clinical
practice was associated with no major peri-procedural neurologic complications and a total elimination of post-procedural
neurologic complications after 30 days. The CGuard EPS has shown itself to be a promising treatment for carotid lesions."
James Barry, PhD, Chief Executive Officer of InspireMD, commented, "We were pleased to see the results of the IRON-GUARD
registry accepted and published in EuroIntervention. These results further validate the positive clinical outcomes of other trials
and registries utilizing CGuardTM EPS and the data is quite consistent with those other clinical trials. To our knowledge, this now
appears to be the largest registry utilizing CGuard. Following on from the very successful Paradigm 101 study, IRON-GUARD is a
further high quality independent registry which continues to give us confidence in CGuard becoming the standard-of-care for
treatment of carotid artery disease due to the significant safety advantages of our device."
EuroIntervention is a monthly peer-reviewed journal of interventional cardiovascular medicine that has become one of the
benchmarks in its field. EuroIntervention is the official journal of EuroPCR and the European Association of Percutaneous
Cardiovascular Interventions (EAPCI). The Journal is endorsed by the European Society of Cardiology (ESC) and has a distinguished
European and International editorial board led by Prof Patrick W. Serruys from the Erasmus MC, Rotterdam.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic
protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal
embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and
peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR and certain warrants
are quoted on the NYSE MKT under the ticker symbol NSPR.WS.
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will,"
"plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing
and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure
regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger,
multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and
reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party
payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our
products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign
jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise
additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or
difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency
exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and
political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may
affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange
Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking statements as a result of new information, future events or
otherwise.
Investor Contacts:
InspireMD, Inc. Craig Shore Chief Financial Officer Phone: 1-888-776-6804 FREE Email: craigs@inspiremd.com
Crescendo Communications, LLC David Waldman Phone: (212) 671-1021 Email: NSPR@crescendo-ir.com
SOURCE: InspireMD, Inc.
